Hutchmed (HCM) said Thursday it completed enrollment for a phase 2 trial in China evaluating fanregratinib in certain patients with intrahepatic cholangiocarcinoma (IHCC), a type of primary bile duct cancer.
The company said the single-arm trial enrolled 87 IHCC patients with fibroblast growth factor receptor 2 fusion/rearrangement, and will assess the drug's efficacy and safety, with the primary endpoint of measuring objective response rate.
Hutchmed expects topline results by late 2025, which could support a new drug application in China if positive, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。